INS and type 1 diabetes mellitus: Early-phase 1, randomized, quadruple-masked, crossover trial (NCT06338553) assessing the safety and efficacy of a single GLP-1Ra dose in combination with teplizumab in participants with stage 2 T1D. Primary outcomes include changes in blood glucose levels, insulin function, and vascular health, as measured by multiple MMTTs conducted pre- and 3-5 months post-teplizumab treatment (57).